Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer
- 31 December 2005
- journal article
- Published by Elsevier BV in Urology
- Vol. 66 (6), 1150-1154
- https://doi.org/10.1016/j.urology.2005.08.053
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Atorvastatin for the Treatment of Mild to Moderate Alzheimer DiseaseArchives of Neurology, 2005
- Statins and cholesterol lowering after a cancer diagnosis: Why not?Urologic Oncology: Seminars and Original Investigations, 2005
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanismsEuropean Journal of Pharmacology, 2004
- Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)The Lancet, 2004
- The Risk of Cancer in Users of StatinsJournal of Clinical Oncology, 2004
- Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trialThe Lancet, 2004
- Oral simvastatin treatment in relapsing-remitting multiple sclerosisThe Lancet, 2004
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998